Bloomage Biotech(SH:688363) Huachuang Securities·2025-10-09 05:08Investment Rating - The report maintains a "Recommendation" rating for Huaxi Biological [2] Core Views - Huaxi Biological is currently undergoing a systematic adjustment phase, with initial positive results on the profit front. The company reported a revenue of 2.261 billion (down 19.57% year-on-year) and a net profit attributable to the parent company of 221 million (down 35.38%) for the first half of 2025. However, the second quarter showed a turning point with a net profit of 119 million, up 20.89% year-on-year [2][3] - The company is focusing on strategic marketing reductions and effective cost control, leading to a recovery in profitability. The gross margin for the first half of 2025 was 70.99% (down 3.53 percentage points), while the net margin was 9.77% (down 2.39 percentage points) [2][3] - The report highlights the resilience of the sales of Class III medical devices, despite a decline in the skin science innovation transformation business, which saw a revenue drop of 33.97% [2][3] Financial Summary - For 2025, the expected total revenue is 4.959 billion (down 7.7% year-on-year), with a projected net profit of 458 million (up 162.9% year-on-year). The earnings per share are expected to be 0.95 yuan, with a price-to-earnings ratio of 58 [4][9] - The company’s total market capitalization is approximately 26.695 billion, with a current share price of 55.42 yuan and a target price of 64.13 yuan [4][5] - The report anticipates a recovery in the core business operations, with projected net profits for 2025, 2026, and 2027 being 458 million, 618 million, and 748 million respectively [2][4]